Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | How can we improve CAR T-cell therapy?

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, gives insight into the steps that can be taken to improve the effectiveness and safety of CAR T-cell therapy, including performing allogeneic stem cell transplants on the patient after CAR T-cell therapy to overcome hematotoxicity, and using smaller adaptor molecules, such as blinatumomab, in combination with universal CAR T-cell products to enhance overall efficacy. Dr Subklewe also expresses her excitement about the amount of CAR T-cell trials that are currently in development or underway.